The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis ; volume:21 ; number:1 ; day:6 ; month:7 ; year:2023 ; pages:1-11 ; date:12.2023
Health research policy and systems ; 21, Heft 1 (6.7.2023), 1-11, 12.2023
- Urheber
-
Vandenplas, Yannick
Simoens, Steven
Wilder, Philippe Van
Vulto, Arnold G.
Huys, Isabelle
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12961-023-01015-4
- URN
-
urn:nbn:de:101:1-2023100509050467256185
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Vandenplas, Yannick
- Simoens, Steven
- Wilder, Philippe Van
- Vulto, Arnold G.
- Huys, Isabelle
- SpringerLink (Online service)
Ähnliche Objekte (12)
Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden
Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals
Images Interrupted
Iran. Interrupted
Interrupted Suite
Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study
The interrupted flirtation
Interrupted halfway through
The interrupted mirage
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden
Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals
Images Interrupted
Iran. Interrupted
Interrupted Suite
Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study
The interrupted flirtation
Interrupted halfway through
The interrupted mirage
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT04: An Ustekinumab Biosimilar
AVT02: An Adalimumab Biosimilar
Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden
Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals
Images Interrupted
Iran. Interrupted
Interrupted Suite
Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study
The interrupted flirtation
Interrupted halfway through
The interrupted mirage
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT04: An Ustekinumab Biosimilar